This review describes trials evaluating the monoclonal antibody pembrolizumab (an immunotherapy that blocks the interaction between PD-L1/PD-L2) as first-line therapy for advanced non-small-cell lung cancer.
Researchers at the Ludwig Institute for Cancer Research (Brussels, Belgium) have discovered a novel mechanism used by tumors to evade immunotherapies.
Find out about the chemical and physical features of nanoparticulate systems that can be tuned to address the anticancer immune response and recent key examples of the exploited strategies, ranging from nanovaccines to NPs revising the tumor immunosuppressive microenvironment, up to immunotherapeutic multimodal NPs.
Could you give us a brief overview of the SCORES trial? The SCORES trial was…
A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry
Discover preliminary data for a new assay workflow to detect the presence of PD-L1 and PD-L2 on the surface of tumor cells that have broken away from the tumor and entered the blood in this research article from Future Science OA.
Nivolumab has been given the green light for nivolumab for head and neck cancer via the Cancer Drug Fund.
PROGRAM OVERVIEW This case-based enduring activity will cover the treatment and management of patients with…
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center (NC, USA) are developing a potential new immunotherapy strategy for melanoma.
In a first of its kind study, blood sample analysis detects genomic alterations that can predict which cancer patients should receive checkpoint inhibitor immunotherapy.
Live event: Thursday 26 October & Friday 27 October 2017
Genome editing enables researchers to build customized cellular models for nearly any gene target, but not without challenges. Merck KGaA, Darmstadt, Germany has developed methods to overcome these challenges and enhance cell line engineering capabilities.